Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more
Cellectar Biosciences Inc (CLRB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.438x
Based on the latest financial reports, Cellectar Biosciences Inc (CLRB) has a cash flow conversion efficiency ratio of -0.438x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.34 Million) by net assets ($9.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cellectar Biosciences Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Cellectar Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cellectar Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectar Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
|
-0.206x |
|
Hanssak Co., Ltd.
KQ:430690
|
-0.013x |
|
KineMaster Corporation
KQ:139670
|
0.040x |
|
SKB Shutters Corporation Bhd
KLSE:7115
|
-0.002x |
|
LianBio
PINK:LIANY
|
0.536x |
|
Foamit Oyj
HE:FOAMIT
|
0.050x |
|
Eden Research plc
PINK:EDNSF
|
-0.066x |
|
DMS S.A. INH. EO 11845
F:DMS1
|
N/A |
Annual Cash Flow Conversion Efficiency for Cellectar Biosciences Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cellectar Biosciences Inc from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.92 Million | $-23.12 Million | -2.331x | +29.98% |
| 2024-12-31 | $14.29 Million | $-47.58 Million | -3.329x | -241.64% |
| 2023-12-31 | $-13.78 Million | $-32.38 Million | 2.350x | +188.84% |
| 2022-12-31 | $9.54 Million | $-25.22 Million | -2.645x | -287.30% |
| 2021-12-31 | $33.05 Million | $-22.57 Million | -0.683x | -168.60% |
| 2020-12-31 | $54.79 Million | $-13.93 Million | -0.254x | +80.30% |
| 2019-12-31 | $9.06 Million | $-11.69 Million | -1.291x | -49.60% |
| 2018-12-31 | $13.26 Million | $-11.44 Million | -0.863x | +15.80% |
| 2017-12-31 | $10.75 Million | $-11.02 Million | -1.025x | -67.52% |
| 2016-12-31 | $13.54 Million | $-8.28 Million | -0.612x | +87.71% |
| 2015-12-31 | $1.65 Million | $-8.21 Million | -4.978x | -505.11% |
| 2014-12-31 | $10.75 Million | $-8.84 Million | -0.823x | +84.73% |
| 2013-12-31 | $1.70 Million | $-9.15 Million | -5.387x | -730.95% |
| 2012-12-31 | $10.16 Million | $-6.59 Million | -0.648x | -2.95% |
| 2011-12-31 | $9.48 Million | $-5.97 Million | -0.630x | +90.26% |
| 2010-12-31 | $1.21 Million | $-7.80 Million | -6.468x | -1738.29% |
| 2009-12-31 | $-26.90 Million | $-10.62 Million | 0.395x | -87.28% |
| 2008-12-31 | $-5.58 Million | $-17.33 Million | 3.104x | +35.27% |
| 2007-12-31 | $-5.87 Million | $-13.47 Million | 2.294x | +476.26% |
| 2006-12-31 | $10.61 Million | $-6.47 Million | -0.610x | -20.00% |
| 2005-12-31 | $4.72 Million | $-2.40 Million | -0.508x | -667.81% |
| 2004-12-31 | $-4.35 Million | $-389.18K | 0.089x | -- |